NCI has issued two Requests for Applications and a Request for Proposals focused on COVID-19 serology and immunology.
The name of the session was a message in and of itself: “Racism and Racial Inequalities in Cancer Research.”
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
People living in rural communities are often located far away from the major cancer centers that offer a full spectrum of treatments, including clinical trials.
Keytruda was approved by FDA as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
FoundationOne CDx has received FDA approval as a companion diagnostic for Keytruda (pembrolizumab), Merck's anti-PD-1 therapy.
Lurbinectedin (Zepzelca) was granted accelerated approval by FDA for adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy.
Gemtuzumab ozogamicin (Mylotarg) was granted an extended indication by FDA for newly-diagnosed CD33-positive acute myeloid leukemia to include pediatric patients 1 month and older.
City of Hope has signed an exclusive worldwide licensing agreement with Scopus BioPharma Inc. to develop and commercialize a City of Hope first-in-class, targeted immuno-oncology gene therapy.
